Algert Global
NPCE icon

Algert Global’s Neuropace NPCE Stock Holding History

Algert Global’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.94M Buy
184,774
+5,218
+3% +$84K 0.03% 728
2026
Q1 		$2.36M Buy
179,556
+6,630
+4% +$99.5K 0.04% 673
2025
Q4 		$2.67M Buy
172,926
+75,437
+77% +$1.01M 0.04% 631
2025
Q3 		$1.01M Buy
97,489
+8,939
+10% +$84.3K 0.02% 837
2025
Q2 		$986K Buy
+88,550
New +$1.11M 0.02% 810

Other funds holding NPCE

Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
First Light Asset Management
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Algert Global's NPCE Position: Q2 2026 in Review

Algert Global increased its Neuropace (NPCE) stake by 2.9% in Q2 2026, buying an estimated $84K and bringing the position to 184,774 shares worth $2.94M. The position accounts for 0.03% of the portfolio, ranked #728.

Algert Global first reported a position in NPCE in Q2 2025 and has held it in 5 quarters since. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Algert Global held 184,774 shares of Neuropace worth $2.94M as of Q2 2026.
  • Algert Global bought 5,218 Neuropace shares in Q2 2026, an estimated $84K.
  • Neuropace made up 0.03% of Algert Global's portfolio in Q2 2026, its #728 holding.
  • Algert Global first reported a position in Neuropace in Q2 2025 and has held it in 5 quarters since.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.